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We previously reported that the maximum tolerated dose
(MTD) of NLT for cGvHD was 200 mg daily for 16 subjects
treated according to a standard 3+3 dose escalation schema
(Chen et al, Blood 2011 118: Abstract 1986). We present new
efﬁcacy data and update prior safety and pharmacokinetic
data in 28 subjects.
Methods: All subjects had extensive steroid dependent/
refractory cGvHD previously treated with  2 agents.
Glucocorticoid (GC) refractory was deﬁned as progressive
cGVHD despite prednisone  0.5 mg/kg/d for  1 month;
steroid dependence was cGvHD requiring prednisone 0.25
mg/kg/d for  3 months. GCs and two other immunosup-
pressants were allowed. Prior imatinib use was allowed. GCs
were tapered as tolerated and other immunosuppressant
dosing remained constant. Safety was determined by
observation of CTCAE v. 4.0 graded adverse events (AEs).
Trough plasma NLT concentrations were determined by LC/
MS before the daytime day 8 dose. Clinical activity of NLTwas
indicated by change in NIH composite skin (D 1) and Lee
symptom skin scores (improvement D 13, worsening D
-20).
Results: Median (range) follow-up was 153 (19-581) days.
Median age (range) was 50.3 (24.5-76.4) years. Mean time
(range) to study enrollment from transplant was 3.8 (1.5-
13.3) years and from cGvHD diagnosis 3.4 (0.3-12.6) years.
The Table shows grade 2-3 AEs possibly or probably attrib-
uted to NLT. So far no grade 4-5 AEs attributed to NLT have
occurred. Median trough concentration of NLT 1 week after
drug initiation at the MTD (n¼23) was 761 nM (range 120-
2290 nM). 26 subjects were evaluable for response. 6 remain
on drug. 20 were removed from the study for progressive
disease (7), toxicity (7), withdrawal of consent (5), and
progression of underlying malignancy (1). Skin disease
responses could be evaluated in 19 subjects. NIH composite
skin score was improved in 4, unchanged in 14, and wors-
ened in 1. Lee symptom skin score was improved in 6 and
unchanged in 13. Among the 7 subjects with progressive
cGvHD, NIH composite or Lee symptom skin score was
unchanged or worsened in 5, improved in 1, and unevaluable
in 1.
Conclusions: Skin improvement in some patients suggests
that NLT 200 mg daily may have clinical activity. Median
trough concentrations that exceeded the IC50s for PDGFRA,
DDR1, DDR2, ABL, and KIT but not NQO2 support this. 200mg
daily, however, is associated with signiﬁcant toxicity. LowerAdverse Event Grade 2
(n¼28)
Grade 3
(n¼28)
Arterial injury 1
Decreased joint ﬂexion 1 1
Dehydration 1
LFT elevation 2 1
Hyponatremia 1
Hypophosphatemia (1 V) 6 3
Increased lipase (3 V) 2 2
Inﬂuenza B 1
Muscle cramping 1 1
Neutropenia (afebrile) 1 1
Pneumocystis carinii pneumonia (1 V) 1
Prolonged QTc 1
Shingles 1 1
Suspected fungal pneumonia 1
URI 1
Worsening Fatigue 2
V DLTdaily doses or alternate day dosing may continue to generate
disease responses while improving tolerability and should be
explored.
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Background: Based on our clinical impression, pts with
grade 3-4 aGVHD have had improved survival in recent years.
In order to explore this observed trend, we evaluated factors
associated with outcome in these pts.
Methods: Pts who had an allogeneic stem cell transplant
(SCT) and who were evaluable for aGVHD by Glucksberg
criteria were included, with SCT segregated into the
following time periods (pds): 1990-1994, 1995-1999, 2000-
2004, and 2005-2011. Pts undergoing cord or haplo-identical
SCT were excluded. We evaluated the impact of variables of
interest and time pd of SCT on overall survival (OS), deﬁned
as time from SCT to death, using univariate and multivariate
analyses.
Results: 959 pts were included (See Table), and 62.5% had
peripheral blood (PB) grafts. Of the 388 unrelated SCT's, 56%
received anti-thymocyte globulin (ATG). Thirty-seven
percent of all pts had reduced-intensity conditioning, and
91% were complete HLA matches. Median recipient age was
47 years (range: 18 e 75), but age increased with time pd of
SCT (See Table; P< .0001). Use of a male donor also increased
with time (P< .0001). Grade 3-4 aGVHD incidence was 16.6%
and signiﬁcantly differed by time pd (See Table;P ¼ .028). It
occurred in 17.6% of pts receiving ATG, compared to 28.7% of
those who did not receive ATG (P ¼ .005). After including
time pd and other donor- and graft-related covariates, only
ATG administration was a signiﬁcant predictor for decreased
grade 3-4 aGVHD (P ¼ .026). Use of PB graft approached
signiﬁcance (P¼ .053). 568 pts have died, andmedian follow-
up is 49 months (range: 3 to 253) in living pts. Median OS for
pts with grade 3-4 aGVHD is 5.0 months, compared to 36.2
and 34.8 months for pts with grade 2 and grade 0-1 aGVHD,
respectively (P < .0001). Among pts with grade 3-4 aGVHD,
median OS is improved with more recent SCT (See Table;P ¼
.018). Having a male donor (P ¼ .0018) and a PB graft (0.017)
are also associated with improved OS in univariate analyses,Table
1990-
1994
1995-
1999
2000-
2004
2005-
2011
All
periods
# of Patients 122 173 207 457 959
Median Age 35 43 46 52 47
Percent male
donors
57 52 57 72 63
Incidence
Grade 3-4
GVHD (%)
18 23.1 17.4 13.3 16.6
Median OS, mo 19.6 25.5 11.0 37.9 22.3
Median OS, mo
(pts with Gr 3-4
GVHD)
3.7 5.7 3.5 8.8 5.0
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use, and recipient age are not. Multivariable analysis was
challenging given the correlation among covariates.
However, male donor is signiﬁcantly associated with
improved OS for pts with grade 3-4 aGVHD in all models,
while time pd is not signiﬁcant when adjusting for other
factors.
Conclusions: While OS for pts with grade 3-4 aGVHD has
improved, it continues to impact >13% of pts and has poor
outcomes. The use of a male donor may predict improved OS
for pts with grade 3-4 aGVHD independent of time pd.
Additional study is warranted to validate these ﬁndings and
improve therapies.425
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Risk of acute GVHD varies among different ethnic population.
Thus, we evaluated potential differences in cGVHD mani-
festations in two ethnic distinct cohorts. The study included
a Brazilian cohort diagnosed with cGVHD by 2005 NIH
criteria who were enrolled in a prospective multicenter
longitudinal study at 5 centers in Brazil and compared with
a North American cohort reported by the cGVHD consortium
(Arai S. et al. Blood 2011). Pts. were assessed using stan-
dardized clinical data forms every 3 months (124 visits). Any
elevation of liver function tests was scored as cGVHD. The
Brazilian study cohort included 36 pts. with a median age of
44 (13-64) years and 21 (58%) were male. At study enroll-
ment, 24 (67%) had classic cGVHD, and 12 (33%) pts. had
overlap subtype (with feature of both acute and chronic).
Distribution of organ involvement attributed to cGVHD for
the Brazilian and the North American cohorts at study
enrollment is shown in the Figure. Liver severity scores at
study enrollment was mild in 10 (34%), moderate in 12 (40%)
and severe in 8 (26%) pts. among Brazilian cohort, and it was
mild in 113 (76%), moderated in 36 (24%) and none severe in
the North American cohort. Overall, cGVHD global severity at
study enrollment was calculated from reported data as mild
in 2 (5.5%), moderate in 17 (47%) and severe in 17 (47%) of
Brazilian cohort compared to 32 (10%),175 (59%) and 91(31%)
in the North American cohort, respectively. Similar to North
American cohort, distribution of global severity was similar
in the Brazilian cohort across 22 incident (enrollment < 3
months of cGVHD diagnosis) and 14 prevalent cases
(enrollment 3 or 6 months after cGVHD diagnosis) and,
between pts. with classic and overlap cGVHD. Prevalence of
organs involvement at study enrollment was signiﬁcant
different between the two population. Compared to theNorth American cohort, the Brazilian cohort had higher rates
of liver involvement (83% vs. 50%; p < .001) and lower rate of
lung (8% vs. 50%; p < .001), respectively. The cause for the
high incidence and severity scores in the liver among the
Brazilian cohort is unknown, but we speculated potential
contributors. For instance, 100% of Brazilian cohort was CMV
positive and pre-emptive treatment for CMV reactivation is
not used after day 100 posttransplant, thus reactivation of
CMV may have contributed to the elevation of liver function
tests. Moreover, it is not standard practice in Brazil to add
ursodiol to treat elevation of liver tests attributed to GVHD,
thus allowing for further potential increase in liver severity
score. The lower rates of lung in the Brazilian cohort may
reﬂect non-standardization of pulmonary function test in
Brazil. In conclusion, prevalence of organ manifestations in
cGVHD varied between the two ethnic distinct cohort
studied. Attention should be taken into consideration when
evaluating prognosis and outcomes in cGVHD in different
ethnic population.
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Background: Acute graft-versus-host disease (aGVHD) is
a frequent complication of allogeneic hematopoietic stem
cell transplantation (HSCT). Although the presence of a skin
eruption is a cornerstone in the diagnosis of aGVHD
according to the Glucksberg criteria and the 2005 NIH
Consensus Conference, speciﬁc cutaneous features such as
morphology and anatomic distribution have not been
studied in a systematic manner. Subsequently, the relative
incidences of speciﬁc skin lesions remain unclear and
contribute to the ongoing challenge of delineating aGVHD
from other commonly seen skin eruptions early after HSCT.
Methods: A retrospective review of all patients receiving an
allogeneic HSCT from 2010 to 2011 at Northwestern Memo-
rial Hospital identiﬁed those individuals with cutaneous
aGVHD. Each case of aGVHD was conﬁrmed by both skin
